rs117906595 (SDK1): astrocytoma and glioma risk
Upload your raw genetic data once, we'll show you which variants you carry and what the research says.
Key takeaways
- This SNP raises risk of high-grade astrocytoma.
- It also increases glioma risk.
- Effect sizes are small but significant.
- Both findings come from the same study.
Key takeaways This SNP raises risk of high-grade astrocytoma. It also increases glioma risk. Effect sizes are small but significant. Both findings come from the same study.
What the research says This SNP is associated with a higher risk of high-grade astrocytoma, reported effect size 3.2 p=6e-7 in about 7 thousand individuals [PMID 36810956]. It also raises the likelihood of high-grade gliomas, reported effect size 2.74 p=1e-5 from the same study [PMID 36810956].
Reported associations
- Astrocytoma (high-grade): this variant raises risk, effect size 3.2 p=6e-7 [PMID 36810956].
- Glioma (high-grade): this variant raises risk, effect size 2.74 p=1e-5 [PMID 36810956].
Evidence quality The association is based on a genome-wide association study of about 7 thousand individuals, yielding a small but statistically significant effect size for both traits [PMID 36810956]. No other studies are provided, so replication beyond this cohort cannot be assessed.
No lifestyle considerations on file for this variant.
Frequently asked questions
What does rs117906595 mean?
This SNP is a genetic marker that has been linked to higher risk of high-grade astrocytoma and gliomas, with small effect sizes.
Is this variant dangerous?
The evidence shows an association but the effect size is modest and not enough to predict disease in individuals.
Can I test for this SNP?
Yes you can order a DNA test that includes SDK1, but it will only show if the variant is present; it does not guarantee disease.